CoRREsponDEnCE
a
40
b

5
30
20
10
7
6
5
4
3
2
1
18
22
26
30
34
38
42
46
Isoform number
t (min)
© 2011 Nature America, Inc. All rights reserved.
Figure 1 Comparison of the pre- and post-change Aranesp batches measured by capillary zone electrophoresis. (a) Relative content of the individual isoforms of the pre-change (n = 18) and the post-change (n = 4) batches. (b) Representative electropherograms; peaks are labeled with the isoform number.





distribution between two sets of batches (Fig. 1a,b). The batches expiring up to April 2010 showed a higher sialylation rate than the batches expiring after September 2010. The average amount of the more highly sialylated isoform number 5 decreased by an average of 10%, whereas the less sialylated isoforms increased 3% (isoform number 4) and 5% (isoform number 3). However, each of the two groups showed a very high batch-to-batch consistency (Fig. 1a). The magnitude might indicate that this change is a consequence of a manufacturing process change. Indeed, in 2008 the European Medicines Agency approved a major process change of Aranesp based on an extensive comparability exercise4. However, although the time frames are
matching, we have no conclusive evidence that
our data reflect this published process change.Rituxan/Mabthera contains a chimeric IgG1 monoclonal antibody against the B-cell surface antigen CD20 (rituximab) as the active ingredient. It is mainly used in the treatment of B-cell malignancies and rheumatoid arthritis. The glycosylation-dependent Fc effector functions are essential contributors to its therapeutic mode of action and clinical efficacy5,6.
We have characterized commercial batches of Rituxan/Mabthera with expiry dates from September 2007 to October 2011 using glycan mapping, cation exchange chromatography (CEX) and antibody-dependent cellular cytotoxicity (ADCC) in vitro bioactivity (Fig. 2). In 2008, an abrupt change in the quality profile became apparent for batches with expiry dates in 2010 or later. The most obvious difference was found in the amount of the C-terminal lysine and N-terminal glutamine variants when analyzed by cation exchange chromatography (Fig. 2a,b and Supplementary Fig. 2a,c). These variants elute as basic variants after the main peak. The post-change batches contain a much smaller amount of these basic variants whose relative amounts are reduced from ~30–50% to ~10%. It should be noted that lysine and glutamine heterogeneity is common for monoclonal
Rel. content (rel. area %)

a

b
c
AD

CC potency (% of reference)
1401201008060
Expiry date


G0 glycan (rel. area %)
G0F-GlcNac G0 G0F Man5
GlcNAc Mannose Fucose Mannose
Expiry datet (min)
Figure 2 Comparison of the different pre- and post-change batches of Rituxan/Mabthera. (a) Exemplary CEX chromatograms. (b) Amount of basic variants of the pre-change (n = 12) and post-change (n = 6) batches as measured by CEX. (c) ADCC potency of the pre-change (n = 11) and post-change (n = 8) batches. (d) Relative amount of the G0 glycan of the pre-change (n = 13) and post-change (n = 11) batches. (e) Exemplary glycan mapping chromatograms. (f) Glycan legend.
nature biotechnology volume 29 number 4 april 2011 311
et al.: Acceptable changes in quality attributes of glycosylated biopharmaceuticals Nature Biotechnology 29, 310-312, 2011 11
glycosylated biopharmaceuticals 1982-1985 1985 - 2005 mAbs & Etanercept The low productivity of cell culture started the trend to build extremely costly, ...
for complex biopharmaceuticals and most are N-glycosylated at an Asparagine. ...In contrast, intact moss plants (protonema) are grown in simple media of ...
for complex biopharmaceuticals and most are N-glycosylated at an Asparagine. ...In contrast, intact moss plants (protonema) are grown in simple media of ...
热门文档